Pedro Augusto Silva dos Santos Rodrigues1, Álvaro Augusto Souza da Cruz Filho2, Helena Mariana Pitangueira Teixeira1, Luciano Gama da Silva Gomes1, Hatilla dos Santos Silva1, Juliana Lopes Rodrigues1, Almirane Lima de Oliveira1, Cinthia Vila Nova Santana2, Gabriela Pimentel Pinheiro das Chagas2, Camila Alexandrina Viana de Figueiredo1, Ryan dos Santos Costa1
J Bras Pneumol.2025;51(4):e20250066
Objective: Given that ß2 agonists constitute the primary treatment for asthma and that treatment response varies as a result of polymorphisms in the ADRB2 gene, we sought to investigate the associations between ADRB2 gene variants and bronchodilator response (BDR) in asthma patients. Methods: A genetic database comprising 813 individuals was analyzed for variants in the ADRB2 gene. A longitudinal analysis of severe asthma patients was performed to evaluate changes in BDR over time. Results: The rs1042713, rs1042714, and rs1042717 variants were associated with age-related changes in BDR in patients with severe asthma. The G allele (rs1042714) and the A allele (rs1042717) were associated with uncontrolled asthma, with carriers of the G46/G79/A252 alleles showing a higher risk of difficult-to-control asthma. Notably, no association was found between these variants and ADRB2 expression levels. Conclusions: Our findings suggest that a genetic panel including ADRB2 variants, as well as age-related differences in BDR, is a useful complementary tool in asthma management.
Keywords: Bronchodilator agents; Beta-2 adrenergic receptor; Genetic variation;; Asthma; Ethnic groups
